Clinical Trial Update: A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS [Phase 1, Phase 2]

View source ↗

Summary

A combined therapy study (deferasirox, vitamin D, azacytidine) in high-risk myelodysplastic syndromes is in Phase 1/Phase 2 with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Deferasirox (Deferasirox)
• Vitamin D (Cholecalciferol)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: MDS | Phase 1, Phase 2 | Status: UNKNOWN